{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"21.9","upperLimit":"34.5","value":"28"},{"groupId":"OG001","lowerLimit":"0","upperLimit":"0","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"208"},{"groupId":"OG001","value":"104"}],"units":"Participants"}],"description":"The proportion of subjects with a best overall response (BOR) of confirmed complete response (CR) or partial response (PR) as determined by the Independent Review Committee (IRC.) Per Response Evaluation Criteria in Solid Tumor Criteria (mRECIST v1.0) for target lesions and assessed by MRI or CT: Complete Response (CR) disappearance of all target lesions; Partial Response (PR) ≥ 30% decrease in the sum of the longest diameter of target lesions; Progressive Disease (PD) ≥ 20% increase in the sum of the longest diameter of target lesions. Overall Response Rate: ORR=CR +PR","groups":[{"description":"XL184 175 mg L-malate salt weight; 138 mg freebase equivalent weight, oral capsules once daily","id":"OG000","title":"XL184 (Cabozantinib)"},{"description":"Oral capsules once daily","id":"OG001","title":"Placebo"}],"paramType":"NUMBER","populationDescription":"The primary analysis Objective Response Rate (ORR) was performed among subset of Intent To Treat (ITT) subjects with measurable disease at baseline (N = 208 cabozantinib, N = 104 placebo) based upon response determined by Independent Radiology Committee (IRC.) Subjects without post-baseline adequate tumor assessments - counted as nonresponders.","reportingStatus":"POSTED","timeFrame":"Assessed at the same time as primary analysis of Progression Free Survival (PFS) data. Assessed at baseline and every 12 weeks until Progressive Disease (PD) up to 34 months.","title":"Objective Response Rate (ORR)","type":"SECONDARY","unitOfMeasure":"% of participants"}